PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsZiconotide
Prialt(ziconotide)
Prialt (ziconotide) is a protein pharmaceutical. Ziconotide was first approved as Prialt on 2004-12-28. It is used to treat chronic pain in the USA. It has been approved in Europe to treat pain and spinal injections. It is known to target voltage-dependent P/Q-type calcium channel subunit alpha-1A and voltage-dependent N-type calcium channel subunit alpha-1B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
therapeuticsD013812
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Prialt (discontinued: Prialt)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ziconotide acetate
Tradename
Company
Number
Date
Products
PRIALTTerSera TherapeuticsN-021060 RX2004-12-28
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
prialtNew Drug Application2023-10-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
chronic painHP_0012532D059350—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ziconotide Acetate, Prialt, Tersera
86530332024-10-01U-48, U-55
87656802024-10-01U-48, U-55
97072702024-10-01U-2084
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02B: Other analgesics and antipyretics in atc
— N02BG: Other analgesics and antipyretics in atc
— N02BG08: Ziconotide
HCPCS
Code
Description
J2278
Injection, ziconotide, 1 microgram
Clinical
Clinical Trials
12 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PainD010146EFO_0003843R52—22116
NeuralgiaD009437EFO_0009430——111—3
Bone marrow diseasesD001855—————1—1
Spinal cord diseasesD013118HP_0002196G95.9———1—1
Peripheral nervous system diseasesD010523HP_0009830G64———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic painD059350HP_0012532——11—35
Spinal cord injuriesD013119EFO_1001919———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intractable painD010148———1——12
NeoplasmsD009369—C80—2———2
Hiv infectionsD015658EFO_0000764B20—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pain managementD059408——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameZiconotide
INNziconotide
Description
Ziconotide, sold under the brand name Prialt, also called intrathecal ziconotide (ITZ) because of its administration route, is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus, a cone snail, it is the synthetic form of an ω-conotoxin peptide. It is 1,000 times as powerful as morphine.
Classification
Protein
Drug classpeptides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC3=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O
Identifiers
PDB—
CAS-ID107452-89-1
RxCUI—
ChEMBL IDCHEMBL4594214
ChEBI ID—
PubChem CID16135415
DrugBankDB06283
UNII ID7I64C51O16 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CACNA1A
CACNA1A
CACNA1B
CACNA1B
Organism
Homo sapiens
Gene name
CACNA1A
Gene synonyms
CACH4, CACN3, CACNL1A4
NCBI Gene ID
773
Protein name
voltage-dependent P/Q-type calcium channel subunit alpha-1A
Protein synonyms
BI, brain calcium channel 1, Brain calcium channel I, calcium channel, L type, alpha-1 polypeptide, Calcium channel, L type, alpha-1 polypeptide isoform 4, calcium channel, voltage-dependent, P/Q type, alpha 1A subunit, fetal brain Ca2+ voltage-gated channel alpha1A pore-forming subunit, Voltage-gated calcium channel subunit alpha Cav2.1
Uniprot ID
Q9UDC4
Mouse ortholog
Cacna1a (12286)
voltage-dependent P/Q-type calcium channel subunit alpha-1A (Q2TPN3)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Prialt – Elan Corporation
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Prialt – Jazz Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,430 documents
View more details
Safety
Black-box Warning
Black-box warning for: Prialt
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,626 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use